Earlier this week I took a look at the five best performing shares on the All Ordinaries (Index: ^AXAO) (ASX: XAO) over the last 12 months.
Whilst those five shares helped carry the index to a 2.6% gain over the period, the five shares below have acted as a drag on it.
These are the five worst performing shares on the All Ordinaries in the last 12 months:
The Innate Immunotherapeutics Ltd (ASX: IIL) share price has fallen 89% in the last 12 months after the biotech company released negative results to its Phase 2b trials in June. Those results found that its MIS416 treatment for multiple sclerosis was no better than a placebo. Unfortunately for shareholders there doesn't seem to be any way back for the company now.
The Quintis Ltd (ASX: QIN) share price has plunged 82% since this time last year following a sudden fall from grace. The declines began earlier this year when short sellers targeted the company, claiming it had a Ponzi-like operation. Since then there has been shock announcement after shock announcement, including the revelation that the company was unaware that it had lost one of its largest supply contracts in December of last year. The company's shares have not traded since May but are expected to resume trading on 1 September 2017. Stay well away would be my advice.
The Blackham Resources Ltd (ASX: BLK) share price has lost 82% of its value in the last 12 months. Despite a rise in the gold price, the gold miner's shares have come under heavy selling pressure this year after strong rains led to the loss of 26 days of open pit mining. Furthermore, the knock on effect of this has been slower than expected dig rates which have significantly reduced the total ore mined.
The Resapp Health Ltd (ASX: RAP) share price is down 77% during the period. Like Innate Immunotherapeutics, the decline in its shares relates to a disappointing study result. According to the results of its Smartcough C study, predefined endpoints for positive percent agreement and negative percent agreement with clinical diagnosis are unlikely to be met. This strikes me as another one to avoid.
The Yowie Group Ltd (ASX: YOW) share price has fallen almost 74% in the last 12 months after a series of profit downgrades sent shareholders to the exits in their droves. As I wrote last month, Yowie released its quarterly update at the end of July which revealed a 23% increase in quarterly revenue. Whilst this is positive growth, it is worth noting that with nine days remaining in the quarter the company provided guidance for 37% growth. Furthermore, it meant the company fell short of its full-year guidance which had already been downgraded three times in the space of 12 months.
